[Ki-1 large cell lymphoma with secondary xanthomatous infiltration of the lesions by chemotherapy].
Moulonguet
I
I
Clinique des Maladies Cutanées, Hôpital Saint-Louis, Paris.
Perrin
P
P
Iskandar
M J
MJ
Flageul
B
B
Verola
O
O
Maillet
M
M
Civatte
J
J
D000368:Aged; D000369:Aged, 80 and over; D000943:Antigens, Differentiation / Q000276:immunology; D000951:Antigens, Neoplasm / Q000276:immunology; D000970:Antineoplastic Agents / Q000627:therapeutic use; D015496:CD4-Positive T-Lymphocytes / Q000276:immunology; D003520:Cyclophosphamide / Q000008:administration & dosage; D006801:Humans; D007150:Immunohistochemistry; D017730:Ki-1 Antigen; D008223:Lymphoma / Q000188:drug therapy / Q000473:pathology* / Q000532:radiotherapy; D008297:Male; D009333:Neck; D011241:Prednisone / Q000627:therapeutic use; D012878:Skin Neoplasms / Q000188:drug therapy / Q000473:pathology* / Q000532:radiotherapy; D013713:Teniposide / Q000008:administration & dosage; D014973:Xanthomatosis / Q000473:pathology
D000943:Antigens, Differentiation; D000951:Antigens, Neoplasm; D000970:Antineoplastic Agents; D017730:Ki-1 Antigen; D003520:Cyclophosphamide; D013713:Teniposide; D011241:Prednisone
Lymphome à grandes cellules Ki1 avec xanthomisation des lésions sous chimiothérapie.